Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Rituximab + Methotrexate Followed by Rituximab + Cytarabine in Elderly Primary CNS Lymphoma
NCT03569995Phase 2Unknown
- Start
- Nov 2018
- Primary completion
- Jun 2024
- Modality
- Monoclonal Antibodies
- Countries
- 1
01
Overview
Phase 2, open-label, single-arm trial of rituximab in primary central nervous system lymphoma (PCNSL). Primary endpoint: 2-year progression free survival rate. Status: unknown.
02
Drugs
rituximab
03
Conditions
primary central nervous system lymphoma (PCNSL)
Beyond the preview
Go deeper on NCT03569995.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT03569995.